Tieteelliset julkaisut

Tulokset kategoriasta yhdiste hakusanalla psykedeelit yleisesti. Takaisin


Psychiatry might need some psychedelic therapy (Johnson MW, 2018)
Julkaisu:International Review of Psychiatry
Tiivistelmä: In historical and modern-day studies, psychedelic drugs have shown promise in managing a variety of psychiatric disorders, but their medical use has often raised controversies. The controversies have related to social, political, and legal challenges.
Yhdiste:Psykedeelit yleisesti
Aihe:Pääkirjoitus
Menetelmät:Pääkirjoitus
Otoskoko:0
Muuta:
Tagit:
DOI:https://doi.org/10.1080/09540261.2018.1509544
URL: https://www.tandfonline.com/doi/full/10.1080/09540261.2018.150954...
LinkkiPysyvä linkki julkaisun sivulle tietokannassamme


Psychedelics – Re-opening the doors of perception (Heal DJ, Henningfield J, Frenguelli BG, Nutt DJ, Smith SL, 2018)


Current perspectives on psychedelic therapy: use of serotonergic hallucinogens in clinical interventions (Garcia-Romeu A, Richards WA, 2018)
Julkaisu:International Review of Psychiatry
Tiivistelmä: Humans have used serotonergic hallucinogens (i.e. psychedelics) for spiritual, ceremonial, and recreational purposes for thousands of years, but their administration as part of a structured therapeutic intervention is still a relatively novel practice within Western medical and psychological frameworks. In the mid-20th century, considerable advances were made in developing therapeutic approaches integrating administration of low (psycholytic) and high (psychedelic) doses of serotonergic hallucinogens for treatment of a variety of conditions, often incorporating psychoanalytic concepts prevalent at that time. This work contributed seminal insights regarding how these substances may be employed with efficacy and safety in targeted therapeutic interventions, including the importance of optimizing set (frame of mind) and setting (therapeutic environment). More recently, clinical and pharmacological research has revisited the effects and therapeutic potential of psychedelics utilizing a variety of approaches. The current article provides an overview of past and present models of psychedelic therapy, and discusses important considerations for future interventions incorporating the use of psychedelics in research and clinical practice.
Yhdiste:Psykedeelit yleisesti
Aihe:Psykedeeliavusteinen psykoterapia yleisesti
Menetelmät:Katsausartikkeli
Otoskoko:0
Muuta:
Tagit:
DOI:https://doi.org/10.1080/09540261.2018.1486289
URL: https://www.tandfonline.com/doi/full/10.1080/09540261.2018.148628...
LinkkiPysyvä linkki julkaisun sivulle tietokannassamme


Awe: a putative mechanism underlying the effects of classic psychedelic-assisted psychotherapy (Hendricks PS, 2018)
Julkaisu:International Review of Psychiatry
Tiivistelmä: A psychological model of classic psychedelic-assisted psychotherapy informed by contemporary scientific data is presented in this paper. It is suggested that classic psychedelic-occasioned mystical experience is characterized by profound awe, a discrete emotion experienced in the presence of a vast stimulus requiring accommodation of mental structures. Awe, in turn, promotes the small self, a construct that, in the extreme, is analogous to those of unitive experience and ego dissolution. The small self is conceptualized as key to understanding the downstream effects of mystical experience occasioned in the context of classic psychedelic-assisted psychotherapy. With this novel theoretical framework in mind, a number of clinical implications and recommendations are provided so as to advance this incipient field of study.
Yhdiste:Psykedeelit yleisesti
Aihe:Psykedeeliavusteinen psykoterapia yleisesti
Menetelmät:Katsausartikkeli
Otoskoko:0
Muuta:
Tagit:
DOI:https://doi.org/10.1080/09540261.2018.1474185
URL: https://www.tandfonline.com/doi/full/10.1080/09540261.2018.147418...
LinkkiPysyvä linkki julkaisun sivulle tietokannassamme


Psychedelics and music: neuroscience and therapeutic implications (Barrett FS, Preller KH, Kaelen M, 2018)
Julkaisu:International Review of Psychiatry
Tiivistelmä: From the beginning of therapeutic research with psychedelics, music listening has been consistently used as a method to guide or support therapeutic experiences during the acute effects of psychedelic drugs. Recent findings point to the potential of music to support meaning-making, emotionality, and mental imagery after the administration of psychedelics, and suggest that music plays an important role in facilitating positive clinical outcomes of psychedelic therapy. This review explores the history of, contemporary research on, and future directions regarding the use of music in psychedelic research and therapy, and argues for more detailed and rigorous investigation of the contribution of music to the treatment of psychiatric disorders within the novel framework of psychedelic therapy.
Yhdiste:Psykedeelit yleisesti
Aihe:Psykedeeliavusteinen psykoterapia yleisesti
Menetelmät:Katsausartikkeli
Otoskoko:0
Muuta:
Tagit:
DOI:https://doi.org/10.1080/09540261.2018.1484342
URL: https://www.tandfonline.com/doi/full/10.1080/09540261.2018.148434...
LinkkiPysyvä linkki julkaisun sivulle tietokannassamme


Psychedelics as anti-inflammatory agents (Flanagan TW, Nichols CD, 2018)
Julkaisu:International Review of Psychiatry
Tiivistelmä: Serotonin (5-hydroxytryptamine, 5-HT)2A receptor agonists have recently emerged as promising new treatment options for a variety of disorders. The recent success of these agonists, also known as psychedelics, like psilocybin for the treatment of anxiety, depression, obsessive-compulsive disorder (OCD), and addiction, has ushered in a renaissance in the way these compounds are perceived in the medical community and populace at large. One emerging therapeutic area that holds significant promise is their use as anti-inflammatory agents. Activation of 5-HT2A receptors produces potent anti-inflammatory effects in animal models of human inflammatory disorders at sub-behavioural levels. This review discusses the role of the 5-HT2A receptor in the inflammatory response, as well as highlight studies using the 5-HT2A agonist (R)-2,5-dimethoxy-4-iodoamphetamine [(R)-DOI] to treat inflammation in cellular and animal models. It also examines potential mechanisms by which 5-HT2A agonists produce their therapeutic effects. Overall, psychedelics regulate inflammatory pathways via novel mechanisms, and may represent a new and exciting treatment strategy for several inflammatory disorders.
Yhdiste:Psykedeelit yleisesti
Aihe:Farmakologia, tulehdus
Menetelmät:Katsausartikkeli
Otoskoko:0
Muuta:
Tagit:
DOI:https://doi.org/10.1080/09540261.2018.1481827
URL: https://www.tandfonline.com/doi/full/10.1080/09540261.2018.148182...
LinkkiPysyvä linkki julkaisun sivulle tietokannassamme


Evaluating the abuse potential of psychedelic drugs as part of the safety pharmacology assessment for medical use in humans (Heal DJ, Gosden J, Smith SL, 2018)
Julkaisu:Neuropharmacology
Tiivistelmä: Psychedelics comprise drugs come from various pharmacological classes including 5-HT2A agonists, indirect 5-HT agonists, e.g., MDMA, NMDA antagonists and κ-opioid receptor agonists. There is resurgence in developing psychedelics to treat psychiatric disorders with high unmet clinical need. Many, but not all, psychedelics are schedule 1 controlled drugs (CDs), i.e., no approved medical use. For existing psychedelics in development, regulatory approval will require a move from schedule 1 to a CD schedule for drugs with medical use, i.e., schedules 2–5.

Although abuse of the psychedelics is well documented, a systematic preclinical and clinical evaluation of the risks they pose in a medical-use setting does not exist. We describe the non-clinical tests required for a regulatory evaluation of abuse/dependence risks, i.e., drug-discrimination, intravenous self-administration and physical dependence liability. A synopsis of the existing data for the various types of psychedelics is provided and we describe our findings with psychedelic drugs in these models. FDA recently issued its guidance on abuse/dependence evaluation of drug-candidates (CDER/FDA, 2017). We critically review the guidance, discuss the impact this document will have on non-clinical abuse/dependence testing, and offer advice on how non-clinical abuse/dependence experiments can be designed to meet not only the expectations of FDA, but also other regulatory agencies. Finally, we offer views on how these non-clinical tests can be refined to provide more meaningful information to aid the assessment of the risks posed by CNS drug-candidates for abuse and physical dependence.
Yhdiste:Psykedeelit yleisesti
Aihe:Päihdekäyttö, Psykedeeliavusteinen psykoterapia yleisesti, haitta-arvio
Menetelmät:Katsausartikkeli
Otoskoko:0
Muuta:
Tagit:
DOI:https://doi.org/10.1016/j.neuropharm.2018.01.049
URL: https://www.sciencedirect.com/science/article/pii/S00283908183005...
LinkkiPysyvä linkki julkaisun sivulle tietokannassamme


Psychedelic drug use in healthy individuals: A review of benefits, costs, and implications for drug policy (Elsey JWB, 2017)
Julkaisu:Drug Science, Policy and Law
Tiivistelmä: The potential of psychedelic drugs in the treatment of mental health problems is increasingly being recognized. However, relatively little thrust has been given to the suggestion that individuals without any mental health problems may benefit from using psychedelic drugs, and that they may have a right to do so.

This review considers contemporary research into the use of psychedelic drugs in healthy individuals, including neurobiological and subjective effects.

In line with findings suggesting positive effects in the treatment of mental health problems, such research highlights the potential of psychedelic drugs for the enhancement of wellbeing even in healthy individuals. The relatively low risk associated with usage does not appear to align with stringent drug laws that impose heavy penalties for their use. Some policy implications, and suggestions for future research, are considered.
Yhdiste:psykedeelit yleisesti
Aihe:päihdekäyttö
Menetelmät:kirjallisuuskatsaus
Otoskoko:0
Muuta:
Tagit: haitallisuusarvio, hyödyllisyysarvio, itselääkintä, päihdepolitiikka
DOI:10.1177/2050324517723232
URL: http://journals.sagepub.com/doi/10.1177/2050324517723232
LinkkiPysyvä linkki julkaisun sivulle tietokannassamme


The Challenging Experience Questionnaire: Characterization of challenging experiences with psilocybin mushrooms. (Barrett FS, Bradstreet MP, Leoutsakos JS, Johnson MW, Griffi.., 2016)
Julkaisu:Journal of Psychopharmacology
Tiivistelmä: Acute adverse psychological reactions to classic hallucinogens ("bad trips" or "challenging experiences"), while usually benign with proper screening, preparation, and support in controlled settings, remain a safety concern in uncontrolled settings (such as illicit use contexts). Anecdotal and case reports suggest potential adverse acute symptoms including affective (panic, depressed mood), cognitive (confusion, feelings of losing sanity), and somatic (nausea, heart palpitation) symptoms.

Responses to items from several hallucinogen-sensitive questionnaires (Hallucinogen Rating Scale, the States of Consciousness Questionnaire, and the Five-Dimensional Altered States of Consciousness questionnaire) in an Internet survey of challenging experiences with the classic hallucinogen psilocybin were used to construct and validate a Challenging Experience Questionnaire.

The stand-alone Challenging Experience Questionnaire was then validated in a separate sample. Seven Challenging Experience Questionnaire factors (grief, fear, death, insanity, isolation, physical distress, and paranoia) provide a phenomenological profile of challenging aspects of experiences with psilocybin. Factor scores were associated with difficulty, meaningfulness, spiritual significance, and change in well-being attributed to the challenging experiences. The factor structure did not differ based on gender or prior struggle with anxiety or depression.

The Challenging Experience Questionnaire provides a basis for future investigation of predictors and outcomes of challenging experiences with classic hallucinogens.
Yhdiste:Psykedeelit yleisesti
Aihe:Yleiset vaikutukset
Menetelmät:Kyselytutkimus, kirjallisuuskatsaus
Otoskoko:0
Muuta:
Tagit:
DOI:10.1177/0269881116678781
URL: http://journals.sagepub.com/doi/abs/10.1177/0269881116678781
LinkkiPysyvä linkki julkaisun sivulle tietokannassamme


Decoding the signaling of a GPCR heteromeric complex reveals a unifying mechanism of action of antipsychotic drugs. (Fribourg M, Moreno JL, Holloway T, Provasi D, Baki L, Mahaja.., 2011)
Julkaisu:Cell
Tiivistelmä: Klassiset serotonergiset psykedeelit aktivoivat 5-HT2A serotoniinireseptorin tavalla, joka heteromerisöi sen metabotrooppisen glutamaattisereptorin (mGluR2) kanssa, salvaten sen toiminnan. Reseptorikompleksin muodostuminen on olennainen psykedeelisille vaikutuksille, koska 5-HT2A agonistit, jotka eivät samalla salpaa mGlu-reseptoreita eivät myöskään tuota psykedeeleille tyypillisiä vaikutuksia.
Yhdiste:psykedeelit yleisesti
Aihe:aivotutkimus
Menetelmät:In vitro
Otoskoko:0
Muuta:
Tagit: 5-HT2A, psykedeelit, toimintamekanismi
DOI:10.1016/j.cell.2011.09.055
URL: https://www.cell.com/cell/fulltext/S0092-8674(11)01272-4
LinkkiPysyvä linkki julkaisun sivulle tietokannassamme